Drugs / PRAFNOSBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04818398 | Apr → Dec 2021 | fibrodysplasia ossificans progressiva | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRAFNOSBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095330 ↗ |
| Known as | DS-6016a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04818398 ↗ |
| Modality | Monoclonal antibody | “DS-6016a, a novel humanized monoclonal anti-ALK2 antibody” PMID 41562506 ↗ Jan 2026 |
| Route | Subcutaneous | “DS-6016a will be administered as a single subcutaneous injection” NCT04818398 ↗ |